Abstract
In The Lancet Oncology, Dominik Dytfeld and colleagues1 report interim findings of the ATLAS study, in which they compared carfilzomib, lenalidomide, and dexamethasone with lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma. Lenalidomide is the cornerstone of maintenance therapy2–4 and alternatives, especially for patients at high risk, have been intensively studied. However, previous trials did not randomly assign patients to lenalidomide, did not lead to licensing, and did not show superiority (even with more intensive regimens).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
